Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors. AnovaOS™ platform to support efficient patient identification and enrolment. Program designed to build upon early success of NEO100 with IDH1 mutated brain tumors (high-grade gliomas) in adult patients. Los Angeles, […]